MedTrace Logo

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

NCT00265642 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C.

The expected total enrollment is 200 patients. Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment (irbesartan or placebo) during two years. The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Irbesartan

one tablet of 150 mg/d during 2 years

DRUG

placebo

one tablet per day during 2 years

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Paul Cales, MD · CHU Angers, Service d'hépato-gastroentérologie, 49933 Angers Cedex 09

  • Fabrice Carrat, MD · Inserm U707 France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2013-04-30
Completion
2013-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265642 on ClinicalTrials.gov